Carisma Therapeutics (CARM) Competitors $0.28 -0.03 (-9.93%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$0.28 +0.00 (+0.71%) As of 09/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. EVGN, INKT, VNRX, ALXO, ANL, CELU, GNTA, MNOV, GANX, and ABVCShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Evogene (EVGN), MiNK Therapeutics (INKT), VolitionRx (VNRX), ALX Oncology (ALXO), Adlai Nortye (ANL), Celularity (CELU), Genenta Science (GNTA), MediciNova (MNOV), Gain Therapeutics (GANX), and ABVC BioPharma (ABVC). These companies are all part of the "medical" sector. Carisma Therapeutics vs. Its Competitors Evogene MiNK Therapeutics VolitionRx ALX Oncology Adlai Nortye Celularity Genenta Science MediciNova Gain Therapeutics ABVC BioPharma Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment. Do analysts rate CARM or EVGN? Carisma Therapeutics currently has a consensus price target of $1.93, suggesting a potential upside of 580.21%. Evogene has a consensus price target of $3.50, suggesting a potential upside of 186.18%. Given Carisma Therapeutics' higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71Evogene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals hold more shares of CARM or EVGN? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor CARM or EVGN? In the previous week, Carisma Therapeutics had 2 more articles in the media than Evogene. MarketBeat recorded 2 mentions for Carisma Therapeutics and 0 mentions for Evogene. Evogene's average media sentiment score of 1.00 beat Carisma Therapeutics' score of -0.50 indicating that Evogene is being referred to more favorably in the news media. Company Overall Sentiment Carisma Therapeutics Negative Evogene Positive Which has more risk and volatility, CARM or EVGN? Carisma Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Which has better valuation and earnings, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.60-$60.48M-$1.56-0.18Evogene$8.51M0.77-$16.49M-$2.25-0.54 Is CARM or EVGN more profitable? Evogene has a net margin of -211.61% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -192.17% Evogene -211.61%-109.96%-38.47% SummaryCarisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.13M$2.55B$5.77B$10.28BDividend YieldN/A57.29%5.74%4.64%P/E Ratio-0.1823.4276.8726.98Price / Sales0.60721.40543.18128.42Price / CashN/A169.7137.1760.63Price / Book-0.425.4313.836.37Net Income-$60.48M$32.95M$3.29B$271.46M7 Day Performance-24.35%2.04%1.57%2.53%1 Month Performance18.91%8.20%6.87%9.42%1 Year Performance-71.14%-2.34%81.58%30.16% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics2.3971 of 5 stars$0.28-9.9%$1.93+580.2%-71.7%$13.13M$19.63M-0.1820News CoverageShort Interest ↑EVGNEvogene3.0954 of 5 stars$1.27+5.6%$3.50+175.6%-55.4%$6.46M$9.44M-0.56140Short Interest ↓Gap UpINKTMiNK Therapeutics3.7392 of 5 stars$15.83+7.0%$37.50+136.9%+107.4%$66.94MN/A-5.5030News CoveragePositive NewsShort Interest ↓VNRXVolitionRx2.1402 of 5 stars$0.61+1.5%$3.50+472.8%+1.6%$65.74M$1.32M-1.7080Gap UpALXOALX Oncology3.742 of 5 stars$1.11-9.0%$3.30+197.3%-49.1%$65.33MN/A-0.5040News CoverageANLAdlai Nortye2.0059 of 5 stars$1.70-2.9%$9.00+429.4%-21.4%$64.57M$5M0.00127Positive NewsCELUCelularity1.7583 of 5 stars$2.11-12.4%$6.00+184.4%-14.5%$64.33M$54.22M-0.66220Positive NewsGNTAGenenta Science2.6114 of 5 stars$3.49-0.3%$25.00+616.3%-7.9%$64.02MN/A0.007Gap UpMNOVMediciNova2.1841 of 5 stars$1.26-2.3%$7.00+455.6%-20.0%$63.27M$134.60K-5.0410GANXGain Therapeutics2.2011 of 5 stars$1.75-0.6%$8.00+357.1%+14.9%$63.27M$50K-2.7820News CoverageABVCABVC BioPharma0.2991 of 5 stars$2.72+2.6%N/A+312.1%$62.39M$510K-16.0030 Related Companies and Tools Related Companies Evogene Alternatives MiNK Therapeutics Alternatives VolitionRx Alternatives ALX Oncology Alternatives Adlai Nortye Alternatives Celularity Alternatives Genenta Science Alternatives MediciNova Alternatives Gain Therapeutics Alternatives ABVC BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts